Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
Hepatitis C drug access: Europe is the new Africa

The remarkably high cure rates being reported with the newest hepatitis C drugs are only likely to be used by a tiny percentage of people who need them.

Published
21 hours ago
From
HIV i-Base
Petition: Equitable access to HCV drugs

We, the undersigned, are organizations of people living with hepatitis C virus (HCV), HIV, and our allies. We believe in equitable access to life-saving treatment for all who need it. We write to express our indignation over Gilead’s pricing and licensing policies for the HCV drug, sofosbuvir.

Published
21 hours ago
From
Petitionbuzz
PREZCOBIX™ (darunavir/cobicistat) approved in the U.S. for the treatment of adults living with HIV-1

Combined fixed-dose tablet of darunavir and cobicistat can help reduce number of pills in a combination antiretroviral treatment regimen.

Published
22 hours ago
From
Janssen press release
U.S. Food and Drug Administration approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the treatment of HIV-1 infection in adults

Evotaz is coformulated to be one pill, once-daily, combining the protease inhibitor atazanavir, which is marketed as Reyataz (atazanavir 200 mg/300 mg) capsules, and cobicistat, a pharmacokinetic enhancer marketed by Gilead Sciences, Inc.

Published
22 hours ago
From
Bristol-Myers Squibb press release
Study Finds HIV Drugs Priced Out of Reach

Drugs to treat H.I.V. and AIDS are being priced out of reach for many patients enrolled in insurance plans through the new health care exchanges, despite warnings that such practices are illegal under the Obama administration's health care law.

Published
29 January 2015
From
New York Times
Russia may face shortage of anti-AIDS drugs in 2015

Russia may face a shortage of anti-AIDS drugs in 2015 due to the current complex situation in the national economy and devaluation of the rouble, according to recent statements of Vadim Pokrovsky, head of the Russian Federal Research and Methodological Center for Prevention and Control of AIDS.

Published
29 January 2015
From
EATG
European Advocates Engage with Biomedical Prevention

The European AIDS Treatment Group and AVAC organized an unprecedented three-day workshop: New Developments in HIV Prevention. See http://eatgavacprevention.tumblr.com for more. In addition to comprehensive updates on product pipelines across the prevention research landscape, the group discussed the anticipation of the first data from European oral PrEP trials and the implications for PrEP access in Europe.

Published
28 January 2015
From
AVAC
MSF response to Gilead announcement on inclusion of hepatitis C drug GS-5816 in voluntary licence

GS-5816 is an important anti-hepatitis C compound that, in combination with sofosbuvir, will greatly simplify treatment for developing countries. However, it appears that none of the terms and conditions of the original licence agreement has been changed, meaning that the concerns that MSF has with the licence agreement remain, including the limited geographic scope of the agreement, restrictions on the production and export of active pharmaceutical ingredient, and the inclusion of an ethically and medically controversial and problematic anti-diversion clause.

Published
27 January 2015
From
Médecins Sans Frontières press release
Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has expanded its hepatitis C generic licensing agreements to include the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C. The expanded agreements will allow Gilead’s India-based partners to manufacture GS-5816 and the single tablet regimen of sofosbuvir/GS-5816, once approved, for distribution in 91 developing countries, which together account for 54 percent of the total worldwide population of individuals infected with the hepatitis C virus (HCV).

Published
27 January 2015
From
Gilead press release
Bill Gates Predicts Two Miracles for AIDS Relief by 2030

Bill Gates said he expects a pair of advances by 2030 that will eliminate most of the damage from AIDS. Improved treatment and the development of a vaccine to prevent new infections are the “two miracles” needed to help turn the tide, the billionaire said Friday at the World Economic Forum in Davos, Switzerland.

Published
26 January 2015
From
Bloomberg
← First12345...463Next →

Filter by country